Orgovyx (Relugolix)

Relugolix, the active ingredient in Orgovyx, the active ingredient in Orgovyx, is a GnRH antagonist presented as a 120 mg tablet for oral use. It treats advanced prostate cancer and metastatic castration-sensitive prostate cancer in men. GNH USA supplies Orgovyx as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Orgovyx as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Orgovyx is a GnRH antagonist used in the management of prostate‑related disease pathways.

- Advanced prostate cancer: helps achieve medical castration levels of testosterone. - Metastatic castration‑sensitive prostate cancer: maintains low testosterone to slow disease progression. - Hormone‑sensitive prostate cancer: used as part of combination therapy to control tumor growth.

Orgovyx may cause a range of adverse reactions, most of which are manageable with monitoring.

Common Side Effects: - Hot flashes - Fatigue - Decreased libido - Headache - Nausea - Diarrhea

Serious or Rare Side Effects: - Cardiovascular events such as myocardial infarction - Severe hypertension - Liver enzyme elevations - Bone fractures - Allergic reactions including rash or angioedema - Seizures (rare)

Before starting Orgovyx, patients should be evaluated for cardiovascular health and liver function, and ongoing monitoring is recommended throughout therapy.

- Cardiovascular assessment: review history of heart disease or stroke. - Liver function monitoring: perform baseline and periodic liver enzyme tests. - Bone health evaluation: consider bone density testing for long‑term use. - Drug interactions: review concomitant medications for potential CYP3A4 interactions. - Pregnancy and lactation: contraindicated in women; safety not established. - Store at ambient temperature: keep below 25 °C, protect from moisture and keep in original packaging.

Orgovyx can interact with several drug classes, requiring careful review of a patient’s medication list.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce relugolix exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase relugolix levels.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may require INR monitoring. - Antihypertensives: blood pressure should be observed for additive effects. - Hormonal therapies: may alter endocrine balance. - Anticonvulsants: monitor for seizure threshold changes.